FSD Pharma Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- FSD Pharma Inc. FSD Pharma Inc. (NASDAQ:HUGE; CSE:HUGE), now operating as Quantum BioPharma Ltd., is a Canada-based biopharmaceutical company focused on researching and developing innovative assets and biotech solutions for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse; its primary pipeline includes Lucid-MS, a patented new chemical entity in Phase 2 clinical trials that prevents and reverses myelin degradation for multiple sclerosis treatment in preclinical models, Lucid-PSYCH for mental health disorders including major depressive disorder, FSD-PEA (formerly FSD201) in preparation for Phase 2 trials targeting inflammatory diseases such as mast cell activation syndrome, and unbuzzd, a proprietary over-the-counter dietary supplement formulation of natural ingredients, vitamins, and minerals to support liver and brain function for rapid relief from alcohol consumption effects like inebriation. The company operates through Biopharmaceutical Innovation and Strategic Investments segments, with the latter generating returns via loans secured by residential or commercial real estate; it maintains subsidiaries including Lucid Psycheceuticals Inc. for lead compound development and FSD Strategic Investments Inc. for its investment portfolio, while retaining a 25.71% ownership stake in Celly Nutrition Corp. (as of March 31, 2024) along with tiered royalties of 7% on unbuzzd sales until $250 million is reached, then 3% in perpetuity, and full rights to pharmaceutical versions of similar products. Founded in 1994 and headquartered in Toronto, Ontario, with additional operations referenced in Cobourg, Ontario, and Phase 1 trials conducted in Australia, the company targets global markets in the multi-billion-dollar multiple sclerosis ($23 billion) and mental health ($238 billion) sectors. Recent developments include completion of a 65:1 share consolidation and name change to Quantum BioPharma Ltd. effective August 15, 2024, with trading under new ticker QNTM on NASDAQ and CSE to regain compliance; successful Phase 1 multiple ascending dose trial for Lucid-MS (Lucid-21-302) in February 2025 showing no safety concerns and tolerability in healthy volunteers, enabling advancement to Phase 2 in MS patients; an exclusive option agreement with the University of Southern California signed June 11, 2024, to evaluate novel dietary supplement technology for unbuzzd and other applications; expansion of its investigative pipeline to include potential weight loss and liver health formulations; receipt of ethics committee and institutional review board approvals for unbuzzd safety and efficacy studies in acute alcohol intoxication; and filing of a USD $700 million federal lawsuit in 2025 against CIBC, RBC, and others alleging stock price manipulation and spoofing.
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation
FSD Pharma Announces Share Consolidation and Name Change
FSD Pharma Is Up 216% Today. What Is Going On With HUGE Stock?
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma
FSD Pharma Files Amended and Restated Material Change Report
FSD Pharma provides Corporate Update
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)